Article ID Journal Published Year Pages File Type
9311706 Urology 2005 6 Pages PDF
Abstract
The COX-2 inhibitor etodolac exhibited an antitumor effect on prostate cancer cell lines in vitro and in vivo, and it might be useful for the treatment of hormone-resistant prostate cancer.
Related Topics
Health Sciences Medicine and Dentistry Nephrology
Preview
Antitumor effects of etodolac, a selective cyclooxygenase-II inhibitor, against human prostate cancer cell lines in vitro and in vivo
Authors
, , , , , ,